title: [Role of radiotherapy of lung cancer].
abstract: Data on the 3-year end results of radiotherapy of inoperable localized nonsmall-cell lung cancer (286) and 5-year (98)--for chemoradiotherapy are compared. Three-year survival after hyperfractionated radiotherapy was 23.7% as compared with 11.3% when standard procedures were used. Five-year survival after hyperfractionated radiotherapy using dose escalation, induction consolidation chemotherapy with iphosphamide, etoposide, cisplatin or carboplatin rose from 3.8 to 24%, while patients were discharged 2-3 weeks earlier.
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Mardynskiĭ
authors.forename: A G
authors.initials: AG
authors.lastname: Zolotkov
authors.forename: D V
authors.initials: DV
authors.lastname: Kudriavtsev
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D019583:Dose Fractionation, Radiation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide